Psychedelic Medicine


Psilocybin: Scientific Research, Practitioner Methods, and the Legal Landscape

Log in to view the recording.

*Exclusive for members.

Thursday, July 22nd at 5 pm Pacific, 8 pm Eastern >> Watch the recording now >>

Join Us For an EXCLUSIVE Panel Discussion for Members of The Psychedelic Medicine Association:

Psilocybin: Scientific Research, Practitioner Methods, and the Legal Landscape

Panel Moderator:

Lynn Marie Morski, MD, ESQ

President - Psychedelic Medicine Association


Rebecca Martinez

Co-founder, Fruiting Bodies Collective

Rebecca Martinez is a queer Xicana writer, parent and community organizer born and raised in Portland, Oregon. She is a co-founder of the Fruiting Bodies Collective, an advocacy group, podcast and education hub at the intersections between healing justice and the psychedelics movement. Rebecca served as the Event & Volunteer Coordinator for the successful Measure 109 campaign, an unprecedented state initiative which creates a legal framework for psilocybin therapy in Oregon. She is also the author of Edge Play: Tales From a Quarter Life Crisis, a memoir about psychedelic healing after family trauma, spiritual abuse, and police violence. She serves on the Health Equity Subcommittee for Oregon's Psilocybin Advisory Board as well as the Board of Advisors for the Plant Medicine Healing Alliance.

Andrew Penn, RN, MS, NP, CNS, APRN-BC

Associate Clinical Professor, University of California

Andrew Penn was trained as an adult nurse practitioner and psychiatric clinical nurse specialist at the University of California, San Francisco. He is board certified as an adult nurse practitioner and psychiatric nurse practitioner by the American Nurses Credentialing Center. Currently, he serves as an Associate Clinical Professor at the University of California-San Francisco School of Nursing. Mr. Penn is a psychiatric nurse practitioner with Kaiser Permanente in Redwood City, California, where he provides psychopharmacological treatment for adult patients and specializes in the treatment of affective disorders and PTSD. He is a former board member of the American Psychiatric Nurses Association, California Chapter, and has presented nationally on improving medication adherence, emerging drugs of abuse, treatment-resistant depression, diagnosis and treatment of bipolar disorder, and the art and science of psychopharmacologic practice. He is a founding member of the Organization of Psychedelic and Ethneogenic Nurses (OPENurses).

Dave Phillips

Training Advisor, TheraPsil

Dave Phillips is passionate about helping individuals and organizations experience greater levels of health.Since 1992 when he first began to see clients with significant childhood and adult trauma, Dave has been actively connected to the world of PTSD treatment.  He was certified as an EMDR therapist in 1993 and has added Neurofeedback and Internal Family Systems as different approaches in treating this complex condition. Recently Dave has been leading Canada’s first legal training program for the use of psilocybin for the treatment of end-of-life anxiety for palliative patients. He holds 2 graduate degrees in counseling psychology and has over 30 years experience in the mental health field including trauma therapy and working with hundreds of companies in multiple industries. On a personal level, Dave is married to Adele and has two grown sons; he loves to golf and is an avid consumer and critic of modern film.

Psilocybin is poised to be a major player in the world of psychedelic medicines. A number of Phase 2 trials on psilocybin are underway, Phase 3 trials are on the near horizon, and psilocybin is scheduled to be available for medical use in Oregon in under two years!

This may have you wondering just how this component of what the counterculture called ‘magic mushrooms’ may soon be able to do for your patients.

We’ve seen trials using psilocybin to address a number of conditions, from depression to eating disorders to migraines. So how does it work and what does therapy with psilocybin look like?

To answer those questions, we are honored to have four panelists on this month’s webinar to cover:

• The results of a number of studies involving psilocybin
• What psilocybin-assisted psychotherapy is and how it’s done
• The development of Oregon’s legalization model and what this effort and decriminalization efforts across the globe may mean for your patients

…and much more!

As always, there will be ample time for audience Q & A, so you’ll get to interact with the panelists directly!

So please join us for this live panel discussion on Thursday, July 22nd at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. And for members, please register for the panel here. A link to the recording will be available afterwards if you cannot make it to the live event.

Hope to see you all on the 22nd!

You can find the Psychedelic Medicine Association on Twitter, LinkedIn and on Facebook.